Key data on economic impact of Bronchiolitis Obliterans Syndrome (BOS) presented at ISHLT 2021
News published by Zambon, whose liposomal cyclosporine A for inhalation (L CsA i), which is in clinical development for the potential treatment of BOS, is administered via an optimized investigational eFlow® Technology nebulizer.